{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:33:04Z","timestamp":1790652784795,"version":"4.1.0"},"reference-count":40,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2025,6,30]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and multiple sclerosis (MS) have both overlapping and distinct MRI lesion features, which vary with imaging timing. This study identified distinguishing MRI characteristics using paired MRIs at clinical attack and remission.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively identified Mayo Clinic patients with MOGAD and MS that: (1) fulfilled respective diagnostic criteria; (2) had paired attack (\u226430 days) and remission MRI scans (\u226512 months) without interval attacks. MRIs were compared between groups for key features.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 43 patients with MOGAD (median age 31 years (range, 3\u201367); 63% female) and 49 patients with MS (median age 39 years (range, 17\u201365); 65% female). Resolution of at least one T2-lesion differentiated MOGAD from MS (sensitivity, (95% CI 77% to 100%), specificity, (95% CI 86% to 99%); Youden\u2019s index (YI)=0.90). Resolution of at least two T2-lesions indicated MOGAD (sensitivity 62% (95% CI 41% to 79%); specificity, 100% (95% CI 94% to 100%); YI=0.62). MOGAD patients were more likely to have normal MRI scans at follow-up compared with MS (brain 14\/44 (32%) vs 0\/60 (0%), p&lt;0.001; spine 21\/27 (78%) vs 7\/36 (19%), p&lt;0.001). In addition, the presence of T1-hypointense, ovoid periventricular T2, and enhancing lesions were more common in MS versus MOGAD at attack and remission and in the spine, longitudinally extensive T2 lesions were more common in MOGAD attacks (8\/27 (30%)).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Paired MRI at attack and remission revealed distinctive characteristics of MOGAD and MS, with greater diagnostic value at remission driven by the discriminating power of T2-lesion resolution. In MOGAD patients with initial parenchymal involvement, a 1-year follow-up MRI may aid diagnosis and serve as a new baseline.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jnnp-2025-336684","type":"journal-article","created":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T17:20:10Z","timestamp":1753032010000},"page":"jnnp-2025-336684","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["MRI characteristics during attack and remission distinguish patients with MOG antibody-associated disease from multiple sclerosis"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9549-6648","authenticated-orcid":false,"given":"Stephanie B","family":"Syc-Mazurek","sequence":"first","affiliation":[{"name":"Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9342-2410","authenticated-orcid":false,"given":"Laura","family":"Cacciaguerra","sequence":"additional","affiliation":[{"name":"Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"IRCCS Ospedale San Raffaele, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8419-8728","authenticated-orcid":false,"given":"Deena A","family":"Tajfirouz","sequence":"additional","affiliation":[{"name":"Neurology, Opthalmology, and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyanka","family":"Redenbaugh","sequence":"additional","affiliation":[{"name":"Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl N","family":"Krecke","sequence":"additional","affiliation":[{"name":"Radiology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0607-904X","authenticated-orcid":false,"given":"Smathorn","family":"Thakolwiboon","sequence":"additional","affiliation":[{"name":"Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Dinoto","sequence":"additional","affiliation":[{"name":"Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1794-4502","authenticated-orcid":false,"given":"Ajay","family":"Madhavan","sequence":"additional","affiliation":[{"name":"Radiology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Mendelt","family":"Tillema","sequence":"additional","affiliation":[{"name":"Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Sebastian","family":"Lopez-Chiriboga","sequence":"additional","affiliation":[{"name":"Neurology, Mayo Clinic, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0116-8035","authenticated-orcid":false,"given":"Cristina","family":"Valencia-Sanchez","sequence":"additional","affiliation":[{"name":"Neurology, Mayo Clinic, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4698-663X","authenticated-orcid":false,"given":"Elia","family":"Sechi","sequence":"additional","affiliation":[{"name":"Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J","family":"Chen","sequence":"additional","affiliation":[{"name":"Neurology, Opthalmology, and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6140-5584","authenticated-orcid":false,"given":"Sean J","family":"Pittock","sequence":"additional","affiliation":[{"name":"Neurology, Laboratory Medicine and Pathology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6661-2910","authenticated-orcid":false,"given":"Eoin P","family":"Flanagan","sequence":"additional","affiliation":[{"name":"Neurology, Laboratory Medicine and Pathology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,7,20]]},"reference":[{"key":"2025072010200438000_jnnp-2025-336684v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(21)00218-0"},{"key":"2025072010200438000_jnnp-2025-336684v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(22)00431-8"},{"key":"2025072010200438000_jnnp-2025-336684v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0112-x"},{"key":"2025072010200438000_jnnp-2025-336684v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00095-8"},{"key":"2025072010200438000_jnnp-2025-336684v1.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-0314-x"},{"key":"2025072010200438000_jnnp-2025-336684v1.6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.neurol.2020.06.016","article-title":"MRI characteristics of MOG-Ab associated disease in adults: An update","volume":"177","author":"Shor","year":"2021","journal-title":"Rev Neurol (Paris)"},{"key":"2025072010200438000_jnnp-2025-336684v1.7","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front Neurol"},{"key":"2025072010200438000_jnnp-2025-336684v1.8","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jamaneurol.2021.0912","article-title":"Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing","volume":"78","author":"Sechi","year":"2021","journal-title":"JAMA Neurol"},{"key":"2025072010200438000_jnnp-2025-336684v1.9","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26502"},{"key":"2025072010200438000_jnnp-2025-336684v1.10","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000213557","article-title":"Clinical Features and Factors Associated With Outcome in Late Adult-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease","volume":"104","author":"Dinoto","year":"2025","journal-title":"Neurology (ECronicon)"},{"key":"2025072010200438000_jnnp-2025-336684v1.11","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz144"},{"key":"2025072010200438000_jnnp-2025-336684v1.12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/13524585211018987","article-title":"Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis","volume":"28","author":"Messina","year":"2022","journal-title":"Mult Scler"},{"key":"2025072010200438000_jnnp-2025-336684v1.13","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2018.14"},{"key":"2025072010200438000_jnnp-2025-336684v1.14","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13641"},{"key":"2025072010200438000_jnnp-2025-336684v1.15","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/jon.13137","article-title":"MRI to differentiate multiple sclerosis, neuromyelitis optica, and myelin oligodendrocyte glycoprotein antibody disease","volume":"33","author":"Carnero Contentti","year":"2023","journal-title":"J Neuroimaging"},{"key":"2025072010200438000_jnnp-2025-336684v1.16","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-314005"},{"key":"2025072010200438000_jnnp-2025-336684v1.17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/brain\/aww350","article-title":"Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain (Bacau)"},{"key":"2025072010200438000_jnnp-2025-336684v1.18","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"key":"2025072010200438000_jnnp-2025-336684v1.19","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/brain\/awac480","article-title":"Clinical and MRI measures to identify non-acute MOG-antibody disease in adults","volume":"146","author":"Cortese","year":"2023","journal-title":"Brain (Bacau)"},{"key":"2025072010200438000_jnnp-2025-336684v1.20","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A8089"},{"key":"2025072010200438000_jnnp-2025-336684v1.21","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-324826"},{"key":"2025072010200438000_jnnp-2025-336684v1.22","first-page":"e1097","article-title":"Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders","volume":"97","author":"Sechi","year":"2021","journal-title":"Neurology (ECronicon)"},{"key":"2025072010200438000_jnnp-2025-336684v1.23","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1177\/13524585231166834","article-title":"Comparison of MRI T2-lesion evolution in pediatric MOGAD, NMOSD, and MS","volume":"29","author":"Redenbaugh","year":"2023","journal-title":"Mult Scler"},{"key":"2025072010200438000_jnnp-2025-336684v1.24","first-page":"e1376","article-title":"Timing and Predictors of T2-Lesion Resolution in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease","volume":"101","author":"Cacciaguerra","year":"2023","journal-title":"Neurology (ECronicon)"},{"key":"2025072010200438000_jnnp-2025-336684v1.25","first-page":"e308","article-title":"Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging","volume":"100","author":"Cortese","year":"2023","journal-title":"Neurology (ECronicon)"},{"key":"2025072010200438000_jnnp-2025-336684v1.26","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-332542"},{"key":"2025072010200438000_jnnp-2025-336684v1.27","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.25957","article-title":"Silent New Brain MRI Lesions in Children with MOG-Antibody Associated Disease","volume":"89","author":"Fadda","year":"2021","journal-title":"Ann Neurol"},{"key":"2025072010200438000_jnnp-2025-336684v1.28","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1212\/WNL.0000000000201263","article-title":"Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody-Associated Disease","volume":"99","author":"Syc-Mazurek","year":"2022","journal-title":"Neurology (ECronicon)"},{"key":"2025072010200438000_jnnp-2025-336684v1.29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37833","article-title":"Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder","volume":"4","author":"Camera","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025072010200438000_jnnp-2025-336684v1.30","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516663034"},{"key":"2025072010200438000_jnnp-2025-336684v1.31","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25909"},{"key":"2025072010200438000_jnnp-2025-336684v1.32","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1212\/01.WNL.0000094316.90240.EB","article-title":"Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985\u20132000","volume":"61","author":"Mayr","year":"2003","journal-title":"Neurology (ECronicon)"},{"key":"2025072010200438000_jnnp-2025-336684v1.33","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"2025072010200438000_jnnp-2025-336684v1.34","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/13524585251313744","article-title":"Testing for myelin oligodendrocyte glycoprotein antibodies: Who, what, where, when, why, and how","volume":"31","author":"Budhram","year":"2025","journal-title":"Mult Scler"},{"key":"2025072010200438000_jnnp-2025-336684v1.35","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200035","article-title":"Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome","volume":"9","author":"Wendel","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025072010200438000_jnnp-2025-336684v1.36","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200183","article-title":"Timing of MOG-IgG Testing Is Key to 2023 MOGAD Diagnostic Criteria","volume":"11","author":"Forcadela","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025072010200438000_jnnp-2025-336684v1.37","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26931"},{"key":"2025072010200438000_jnnp-2025-336684v1.38","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/acn3.52310","article-title":"Real-world clinical experience with serum MOG and AQP4 antibody testing by live versus fixed cell-based assay","volume":"12","author":"Said","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"2025072010200438000_jnnp-2025-336684v1.39","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211007086"},{"key":"2025072010200438000_jnnp-2025-336684v1.40","first-page":"e1418","article-title":"Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder","volume":"100","author":"Cacciaguerra","year":"2023","journal-title":"Neurology (ECronicon)"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2025-336684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T17:20:13Z","timestamp":1753032013000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2025-336684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,20]]},"references-count":40,"alternative-id":["10.1136\/jnnp-2025-336684"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2025-336684","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,20]]}}}